Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 11/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | CLPP | Q16740 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.36 |
| ▸ | LONP1 | P36776 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162221 | 0.90 | PSMB5 (0.49) | PSMB5NPY4RNPY5RNPY1RCLPP | |
| SCHEMBL15291263 | 0.90 | PSMB5 (0.43) | PSMB5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL3170634 | 0.89 | CLPP (0.45) | PSMB5CLPPPSMB1PSMB2LONP1 | |
| SCHEMBL3170557 | 0.88 | PSMB5 (0.51) | PSMB5NPY4RNPY5RNPY1RCLPP | |
| SCHEMBL607118 | 0.87 | NMT2 (0.38) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL12754546 | 0.86 | PSMB5 (0.40) | PSMB5NPY4RNPY5RNPY1RCLPP | |
| SCHEMBL607117 | 0.85 | NPY4R (0.35) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL3161735 | 0.84 | PSMB5 (0.40) | PSMB5NPY4RNPY5RNPY1RCLPP | |
| SCHEMBL12754554 | 0.84 | PSMB5 (0.41) | PSMB5NPY4RNPY5RNPY1RCLPP | |
| SCHEMBL12754523 | 0.84 | PSMB5 (0.43) | PSMB5NPY4RNPY5RNPY1RCLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885NPY4R 4558/4885NPY5R 4469/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885NPY4R 4558/4885NPY5R 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.